The presence of the anti-MDA-5 antibody in patients with CADM-associated RPIPs is known to indicate a poor prognosis: its titer reflects disease activity and responses to treatment [3–5]. This evidence concerns the gene IFIH1 and clinically amyopathic dermatomyositis.